Dr. Graham Colditz, M.D., DrPH
Claim this profileWashington University School of Medicine
Studies Colorectal Cancer
Studies Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
5 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Graham Colditz, M.D., DrPH is currently running
Behavioral Weight Loss + Progestin
for Endometrial Hyperplasia
Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.
Recruiting1 award Phase 2
Genetic Results Return
for Cancer Patients
The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.
Recruiting1 award N/A
More about Graham Colditz, M.D., DrPH
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Graham Colditz, M.D., DrPH has experience with
- Progestin
- Participant Engagement And Genomic Result Return
- Denosumab
- Colorectal Cancer Toolkit
- Semaglutide
- Telemedicine Behavioral Weight Intervention
Breakdown of trials Graham Colditz, M.D., DrPH has run
Colorectal Cancer
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Mammary Gland Hyperplasia
Endometrial Hyperplasia
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Graham Colditz, M.D., DrPH specialize in?
Graham Colditz, M.D., DrPH focuses on Colorectal Cancer and Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia. In particular, much of their work with Colorectal Cancer has involved treating patients, or patients who are undergoing treatment.
Is Graham Colditz, M.D., DrPH currently recruiting for clinical trials?
Yes, Graham Colditz, M.D., DrPH is currently recruiting for 3 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Graham Colditz, M.D., DrPH has studied deeply?
Yes, Graham Colditz, M.D., DrPH has studied treatments such as Progestin, Participant Engagement and Genomic Result Return, Denosumab.
What is the best way to schedule an appointment with Graham Colditz, M.D., DrPH?
Apply for one of the trials that Graham Colditz, M.D., DrPH is conducting.
What is the office address of Graham Colditz, M.D., DrPH?
The office of Graham Colditz, M.D., DrPH is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.